cloudfront
  • info@reportsandmarkets.com
  • +44-020-3286-9338 (UK) | +1-214-736-7666 (US) | +1-740-994-0111 (US)
  • Sign In
  • Register

Report Detail



Pharma & Healthcare2018-2023 Global Parkinsons Disease Drugs Consumption Market Report

  • RnM2417850
  • |
  • 14 September, 2018
  • |
  • Global
  • |
  • 164 pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Parkinsons Disease Drugs market for 2018-2023.

Parkinson's disease (PD) is a long-term degenerative disorder of the central nervous system that mainly affects the motor system.The symptoms generally come on slowly over time.Early in the disease, the most obvious are shaking, rigidity, slowness of movement, and difficulty with walking.Thinking and behavioral problems may also occur.Dementia becomes common in the advanced stages of the disease.Depression and anxiety are also common, occurring in more than a third of people with PD.Other symptoms include sensory, sleep, and emotional problems.The main motor symptoms are collectively called "parkinsonism", or a "parkinsonian syndrome"
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Parkinsons Disease Drugs in US$ by following Product Segments.: Clinical, Experiment
Company profiles are primarily based on public domain information including company
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm

Over the next five years, LPI(LP Information) projects that Parkinsons Disease Drugs will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Parkinsons Disease Drugs market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:
Clinical
Experiment
Segmentation by application:
Treament
Prevention

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Parkinsons Disease Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Parkinsons Disease Drugs market by identifying its various subsegments.
Focuses on the key global Parkinsons Disease Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Parkinsons Disease Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Parkinsons Disease Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.


Table of Contents

2018-2023 Global Parkinsons Disease Drugs Consumption Market Report

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Parkinsons Disease Drugs Consumption 2013-2023
2.1.2 Parkinsons Disease Drugs Consumption CAGR by Region
2.2 Parkinsons Disease Drugs Segment by Type
2.2.1 Clinical
2.2.2 Experiment
2.3 Parkinsons Disease Drugs Consumption by Type
2.3.1 Global Parkinsons Disease Drugs Consumption Market Share by Type (2013-2018)
2.3.2 Global Parkinsons Disease Drugs Revenue and Market Share by Type (2013-2018)
2.3.3 Global Parkinsons Disease Drugs Sale Price by Type (2013-2018)
2.4 Parkinsons Disease Drugs Segment by Application
2.4.1 Treament
2.4.2 Prevention
2.5 Parkinsons Disease Drugs Consumption by Application
2.5.1 Global Parkinsons Disease Drugs Consumption Market Share by Application (2013-2018)
2.5.2 Global Parkinsons Disease Drugs Value and Market Share by Application (2013-2018)
2.5.3 Global Parkinsons Disease Drugs Sale Price by Application (2013-2018)

3 Global Parkinsons Disease Drugs by Players
3.1 Global Parkinsons Disease Drugs Sales Market Share by Players
3.1.1 Global Parkinsons Disease Drugs Sales by Players (2016-2018)
3.1.2 Global Parkinsons Disease Drugs Sales Market Share by Players (2016-2018)
3.2 Global Parkinsons Disease Drugs Revenue Market Share by Players
3.2.1 Global Parkinsons Disease Drugs Revenue by Players (2016-2018)
3.2.2 Global Parkinsons Disease Drugs Revenue Market Share by Players (2016-2018)
3.3 Global Parkinsons Disease Drugs Sale Price by Players
3.4 Global Parkinsons Disease Drugs Manufacturing Base Distribution, Sales Area, Product Types by Players
3.4.1 Global Parkinsons Disease Drugs Manufacturing Base Distribution and Sales Area by Players
3.4.2 Players Parkinsons Disease Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Parkinsons Disease Drugs by Regions
4.1 Parkinsons Disease Drugs by Regions
4.1.1 Global Parkinsons Disease Drugs Consumption by Regions
4.1.2 Global Parkinsons Disease Drugs Value by Regions
4.2 Americas Parkinsons Disease Drugs Consumption Growth
4.3 APAC Parkinsons Disease Drugs Consumption Growth
4.4 Europe Parkinsons Disease Drugs Consumption Growth
4.5 Middle East & Africa Parkinsons Disease Drugs Consumption Growth

5 Americas
5.1 Americas Parkinsons Disease Drugs Consumption by Countries
5.1.1 Americas Parkinsons Disease Drugs Consumption by Countries (2013-2018)
5.1.2 Americas Parkinsons Disease Drugs Value by Countries (2013-2018)
5.2 Americas Parkinsons Disease Drugs Consumption by Type
5.3 Americas Parkinsons Disease Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Parkinsons Disease Drugs Consumption by Countries
6.1.1 APAC Parkinsons Disease Drugs Consumption by Countries (2013-2018)
6.1.2 APAC Parkinsons Disease Drugs Value by Countries (2013-2018)
6.2 APAC Parkinsons Disease Drugs Consumption by Type
6.3 APAC Parkinsons Disease Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe
7.1 Europe Parkinsons Disease Drugs by Countries
7.1.1 Europe Parkinsons Disease Drugs Consumption by Countries (2013-2018)
7.1.2 Europe Parkinsons Disease Drugs Value by Countries (2013-2018)
7.2 Europe Parkinsons Disease Drugs Consumption by Type
7.3 Europe Parkinsons Disease Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Parkinsons Disease Drugs by Countries
8.1.1 Middle East & Africa Parkinsons Disease Drugs Consumption by Countries (2013-2018)
8.1.2 Middle East & Africa Parkinsons Disease Drugs Value by Countries (2013-2018)
8.2 Middle East & Africa Parkinsons Disease Drugs Consumption by Type
8.3 Middle East & Africa Parkinsons Disease Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.2 Parkinsons Disease Drugs Distributors
10.3 Parkinsons Disease Drugs Customer

11 Global Parkinsons Disease Drugs Market Forecast
11.1 Global Parkinsons Disease Drugs Consumption Forecast (2018-2023)
11.2 Global Parkinsons Disease Drugs Forecast by Regions
11.2.1 Global Parkinsons Disease Drugs Forecast by Regions (2018-2023)
11.2.2 Global Parkinsons Disease Drugs Value Forecast by Regions (2018-2023)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Parkinsons Disease Drugs Forecast by Type
11.8 Global Parkinsons Disease Drugs Forecast by Application

12 Key Players Analysis
12.1 Johnson & Johnson
12.1.1 Company Details
12.1.2 Parkinsons Disease Drugs Product Offered
12.1.3 Johnson & Johnson Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.1.4 Main Business Overview
12.1.5 Johnson & Johnson News
12.2 Gilead Sciences
12.2.1 Company Details
12.2.2 Parkinsons Disease Drugs Product Offered
12.2.3 Gilead Sciences Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.2.4 Main Business Overview
12.2.5 Gilead Sciences News
12.3 Pacira
12.3.1 Company Details
12.3.2 Parkinsons Disease Drugs Product Offered
12.3.3 Pacira Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.3.4 Main Business Overview
12.3.5 Pacira News
12.4 Sun Pharmaceutical
12.4.1 Company Details
12.4.2 Parkinsons Disease Drugs Product Offered
12.4.3 Sun Pharmaceutical Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.4.4 Main Business Overview
12.4.5 Sun Pharmaceutical News
12.5 Luye Pharma
12.5.1 Company Details
12.5.2 Parkinsons Disease Drugs Product Offered
12.5.3 Luye Pharma Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.5.4 Main Business Overview
12.5.5 Luye Pharma News
12.6 Sigma-Tau Group
12.6.1 Company Details
12.6.2 Parkinsons Disease Drugs Product Offered
12.6.3 Sigma-Tau Group Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.6.4 Main Business Overview
12.6.5 Sigma-Tau Group News
12.7 Fudan-Zhangjiang
12.7.1 Company Details
12.7.2 Parkinsons Disease Drugs Product Offered
12.7.3 Fudan-Zhangjiang Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.7.4 Main Business Overview
12.7.5 Fudan-Zhangjiang News
12.8 Teva Pharmaceutical
12.8.1 Company Details
12.8.2 Parkinsons Disease Drugs Product Offered
12.8.3 Teva Pharmaceutical Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.8.4 Main Business Overview
12.8.5 Teva Pharmaceutical News
12.9 CSPC
12.9.1 Company Details
12.9.2 Parkinsons Disease Drugs Product Offered
12.9.3 CSPC Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.9.4 Main Business Overview
12.9.5 CSPC News
12.10 Novartis
12.10.1 Company Details
12.10.2 Parkinsons Disease Drugs Product Offered
12.10.3 Novartis Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.10.4 Main Business Overview
12.10.5 Novartis News
12.11 Kingond Pharm

13 Research Findings and Conclusion


captcha
Enter the code in the box:


captcha
Enter the code in the box:

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.


captcha
Enter the code in the box:



Summary:
Get latest Market Research Reports on Parkinsons Disease Drugs . Industry analysis & Market Report on Parkinsons Disease Drugs is a syndicated market report, published as 2018-2023 Global Parkinsons Disease Drugs Consumption Market Report. It is complete Research Study and Industry Analysis of Parkinsons Disease Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$4,660.00
$6,990.00
$9,320.00
3,129.19
4,693.79
6,258.38
4,288.13
6,432.20
8,576.26
564,512.40
846,768.60
1,129,024.80
309,020.44
463,530.67
618,040.89
Add To Cart Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report